Regulations.gov document
Exhibit 1 - "Caraco Letter to FDA/CDER, re: ANDA 77-571/Repaglinide, May 29, 2009"…
Supporting & Related Material · FDA-2008-P-0343 · posted Jun 17, 2009
Key facts
| Document ID | FDA-2008-P-0343-0021 |
|---|---|
| Title | Exhibit 1 - "Caraco Letter to FDA/CDER , re: ANDA 77-571/Repaglinide, May 29, 2009" - [Caraco Pharmaceuticals Laboratories, LTD - (Winston & Strawn LLP) - Reply Comment] re FDA-2008-P-0343-0020 |
| Document type | Supporting & Related Material |
| Subtype | RC-Reply Comment (Supporting and Related Material) |
| Agency | FDA |
| Docket | FDA-2008-P-0343 |
| Posted | Jun 17, 2009 |
| Effective date | May 29, 2009 |
At a glance
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: